Research
Cellular
Semaglutide was associated with lower cardiovascular events than metformin, DPP-4 and SGLT2 inhibitors.
Semaglutide may be a preferable option for patients at risk of cardiovascular events compared to other medications.
StrongSupportsmedium confidence
In propensity-matched comparisons during the landmark period, semaglutide was associated with lower cardiovascular events than metformin, DPP-4 and SGLT2 inhibitors.
Why this rating
Based on a large cohort analysis.
Source
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
Karthik Murugadoss et al. · medRxiv · 2026
DOI 10.64898/2026.04.02.26350077
cohort · n=505874Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Higher maximum semaglutide dose was associated with lower post-landmark risk of all-cause mortality (RR 0.42, p<0.001) and composite cardiovascular events (RR 0.51, p<0.001).Strong
- Greater achieved weight loss during the landmark period did not show a consistent association with lower post-landmark cardiovascular risk.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →